Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 61 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Primary Progressive Aphasia, Behavioral Variant of Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant
Interventions
F-18 AV 1451
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
PPA, Non-fluent Aphasia, Apraxia of Speech, Primary Progressive Non-fluent Aphasia, Primary Progressive Aphasia
Interventions
AV-1451
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects

NCT04474405
Conditions
Alzheimer Disease
Interventions
Flortaucipir F18, Brain PET Scan, Whole body PET scan, Florbetapir F 18, Brain MRI
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
20 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Cypress, California • Newport Beach, California
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations

NCT02676843
Conditions
Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD), Tauopathies
Interventions
18F-AV-1451
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Alzheimer Disease
Interventions
flortaucipir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
Not listed
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
22
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 16 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Tau PET Imaging in the NACC Study Cohort

NCT03189485
Conditions
Normal Controls, MCI
Interventions
the radiotracer 18F-AV-1451
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
60 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed No phase listed Observational

Tau Imaging in Young Onset Dementia

NCT02289118
Conditions
Alzheimer's Disease, Early Onset, Logopenic Progressive Aphasia, Posterior Cortical Atrophy (PCA)
Interventions
[18F]-T807 imaging tracer
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Withdrawn Not applicable Interventional Accepts healthy volunteers

Tau Tracer Comparison in Healthy Controls and Alzheimer's Disease Patients

NCT03939780
Conditions
Healthy, Alzheimer Disease
Interventions
[F18]RO-948, [F18]MK-6240, [F18]AV1451
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Recruiting Not applicable Interventional Accepts healthy volunteers

A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy

NCT02605785
Conditions
Progressive Supranuclear Palsy
Interventions
F-18 AV 1451
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years and older
Enrollment
332 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 2 Interventional Results available

Tau Imaging of Chronic Traumatic Encephalopathy

NCT02191267
Conditions
Chronic Traumatic Encephalopathy
Interventions
[F18]-T807, [F18]-Florbetapir, MRI/MRS, Genetic Analysis for Genetic Risk Score for Tau.
Radiation · Device · Genetic
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 69 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative 4

NCT05617014
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Dementia
Interventions
Neuraceq, Amyvid, Tauvid, MK-6240, NAV4694, PI-2620
Radiation
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
62
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 46 more
Conditions
Primary Progressive Aphasia With Suspected Alzheimer's Disease
Interventions
18F-AV-1451, PET
Drug · Device
Lead sponsor
University of Chicago
Other
Eligibility
20 Years to 100 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Alzheimer Disease, Progressive Posterior Cortical Dysfunction (PPCD)
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
45 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Alzheimer's Disease
Interventions
LY3202626, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
49
States / cities
Irvine, California • Sacramento, California • San Diego, California + 40 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects

NCT01992380
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Newport Beach, California • New Haven, Connecticut
Conditions
Alzheimer Disease
Interventions
Flortaucipir F18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
60 Years to 85 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
San Diego, California • Santa Ana, California • Delray Beach, Florida + 6 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of Flortaucipir F 18

NCT02278367
Conditions
Alzheimer's Disease, Traumatic Brain Injury, Depression
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
5
States / cities
Phoenix, Arizona • New Haven, Connecticut • Las Vegas, Nevada + 2 more
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease

NCT05361382
Conditions
Alzheimer Disease
Interventions
18F-Flortaucipir radiopharmaceutical, 18F-MK-6240 radiopharmaceutical, Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol)
Drug
Lead sponsor
Tharick Pascoal
Other
Eligibility
18 Years to 90 Years
Enrollment
822 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
7
States / cities
Berkeley, California • San Francisco, California • Rochester, Minnesota + 4 more
Conditions
Alzheimer Disease
Interventions
[11C]-Pittsburgh Compound B ([11C]PiB), F 18 AV-1451 (Flortaucipir)
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Atypical Alzheimer's Disease, Logopenic Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA), Alzheimer Disease, Alzheimer Disease, Early Onset, Amnestic Disorder, Amnestic Symptoms, Amnestic Mild Cognitive Disorder
Interventions
F-18 AV 1451, C-11 PiB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Alzheimer Disease
Interventions
Flortaucipir F18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
60 Years to 85 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
9
States / cities
Irvine, California • Delray Beach, Florida • Fort Myers, Florida + 6 more
Recruiting No phase listed Observational Accepts healthy volunteers

Imaging Studies in Corticobasal Syndrome

NCT07000851
Conditions
Cortico Basal Degeneration, Corticobasal Syndrome, Corticobasal Syndrome(CBS), Corticobasal Degeneration, Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS)
Interventions
C-11 ER176 Radiotracer, C-11 PiB, AV1451 Tau
Diagnostic Test
Lead sponsor
Jennifer Whitwell
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Completed No phase listed Observational Accepts healthy volunteers

Continuation of The Kronos Early Estrogen Prevention Study (KEEPS)

NCT03718494
Conditions
Alzheimer Dementia
Interventions
Brain Magnetic Resonance Imaging (MRI), F-18 Florbetapir Positron Emission Tomography (PET) Imaging, F-18 AV-1451 Positron Emission Tomography (PET) Imaging, Neuropsychological Testing
Diagnostic Test · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
49 Years to 72 Years · Female only
Enrollment
299 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
6
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 3 more